MATTHEW R PINCUS, MD,PHD
Medical Practice at Poly Pl, Brooklyn, NY
License number
New York 155257
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
800 Poly Pl, Brooklyn, NY 11209
Phone
(718) 630-3688
Personal information
See more information about MATTHEW R PINCUS at radaris.comName
Address
Phone
42 Clinton St APT 20, New York, NY 10002
8750 204Th St APT B42, Hollis, NY 11423
733 Park Ave #25FL, New York, NY 10021
4 Oakdale Ct, Ridge, NY 11961
405 W 14Th St, New York, NY 10014
Professional information
See more information about MATTHEW R PINCUS at trustoria.com
Matthew R Pincus, Brooklyn NY
Matthew R Pincus, Brooklyn NY
Specialties:
Pathologist
Address:
800 Poly Pl, Brooklyn, NY 11209
Education:
State University of New York Downstate Medical Center, College of Medicine - Doctor of Medicine
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Pathology
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Peptidomimetics For The Treatment Of Hiv Infection
Peptidomimetics For The Treatment Of Hiv Infection
US Patent:
5990172, Nov 23, 1999
Filed:
Feb 27, 1997
Appl. No.:
8/807473
Inventors:
Matthew R. Pincus - Brooklyn NY
Andrew S. Kende - Pittsford NY
Joseph J. Hlavka - Tuxedo Park NY
Henry B. Abajian - Hillsdale NJ
Andrew S. Kende - Pittsford NY
Joseph J. Hlavka - Tuxedo Park NY
Henry B. Abajian - Hillsdale NJ
Assignee:
Innapharma, Inc. - Suffern NY
International Classification:
A61K 31165, C07C23305
US Classification:
514621
Abstract:
This invention provides peptidomimetics which bind to T4 or CD4 cell receptors and are useful in inhibiting viral infectivity by viruses which bind to T4 cell receptors. More specifically, peptidomimetics of this invention can alleviate symptoms of AIDS by inhibiting binding of HIV, the virus associated with AIDS, to receptor sites in human cells susceptible to HIV infection. These peptidomimetics, in particular, inhibit binding of HIV to cells of brain membrane and the immune system. They also display substantially longer half-lives in vivo than peptide T. The compounds of this invention which bind to T4 or CD4 receptors and thereby inhibit binding of HIV, alone or in combination with one another, can be used to alleviate AIDS symptoms and ameliorate symptoms of HIV infection, especially neuronal dementias and Kaposi's sarcoma. The compounds of this invention, alone or in combination, can further be used to prevent development of AIDS in persons who might become exposed to HIV.
Peptides Selectively Lethal To Malignant And Transformed Mammalian Cells
Peptides Selectively Lethal To Malignant And Transformed Mammalian Cells
US Patent:
2005024, Nov 3, 2005
Filed:
Dec 21, 2004
Appl. No.:
11/019894
Inventors:
Matthew Pincus - Brooklyn NY, US
International Classification:
A61K038/10, A61K038/08, C07K007/08
US Classification:
514013000, 514014000, 514015000, 530326000, 530327000, 530328000
Abstract:
The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. In order to reduce proteolysis of a subject peptide, one or more D-amino acids may be substituted for the corresponding L-amino acids in the p53 portion and/or the membrane-penetrating leader of a subject peptide. Further, a pseudopeptide bond or a retro-inverso pseudopeptide bond may be substituted for one or more peptide bonds in either or both of the p53 sequence or membrane-penetrating leader sequence in order to render a subject peptide less susceptible to proteolysis. In addition, both the membrane-penetrating leader sequence and the p53 portion of a subject peptide may comprise retro-inverso, and partially modified retro-inverso isomers. Such isomers are less susceptible to proteolysis and therefore have prolonged half-lives. The subject peptides are useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membrane-penetrating leader sequence are also provided as are methods of assessing the level of effectiveness of a subject peptide in killing malignant, transformed, or neoplastic cells in vitro.
Phenotypic Reversion Of Pancreatic Carcinoma Cells
Phenotypic Reversion Of Pancreatic Carcinoma Cells
US Patent:
2006010, May 18, 2006
Filed:
May 31, 2005
Appl. No.:
11/142051
Inventors:
Matthew Pincus - Brooklyn NY, US
Josef Michl - Little Neck NY, US
Josef Michl - Little Neck NY, US
International Classification:
A61K 38/10, A61K 38/08, C07K 7/08
US Classification:
514013000, 514014000, 514015000, 530326000, 530327000, 530328000
Abstract:
The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
Peptidomimetics Inhibiting The Oncogenic Action Of P21 Ras
Peptidomimetics Inhibiting The Oncogenic Action Of P21 Ras
US Patent:
5910478, Jun 8, 1999
Filed:
Sep 20, 1996
Appl. No.:
8/718270
Inventors:
Joseph J. Hlavka - Tuxedo Park NY
John Fowler Noble - Pomona NY
Henry Baxter Abajian - Hillsdale NJ
Andrew S. Kende - Pittsford NY
Matthew R. Pincus - Brooklyn NY
John Fowler Noble - Pomona NY
Henry Baxter Abajian - Hillsdale NJ
Andrew S. Kende - Pittsford NY
Matthew R. Pincus - Brooklyn NY
Assignee:
Innapharma, Inc. - Upper Saddle River NJ
International Classification:
A61K 3800
US Classification:
514 9
Abstract:
The present invention provides peptides, cyclized peptides and peptidomimetics which inhibit the oncogenic and/or transforming activity of the p21 ras protein, pharmaceutical compositions containing at least one of the ras-inhibiting peptides, cyclized peptides and peptidomimetics, and methods for inhibiting the ras-mediated oncogenic and/or transformation process in mammalian cells or tissues.
Phenotypic Reversion Of Pancreatic Carcinoma Cells
Phenotypic Reversion Of Pancreatic Carcinoma Cells
US Patent:
2013006, Mar 14, 2013
Filed:
Nov 15, 2012
Appl. No.:
13/677876
Inventors:
Matthew Pincus - Brooklyn NY, US
Josef Michl - Little Neck NY, US
Josef Michl - Little Neck NY, US
International Classification:
A61K 31/711, A61P 35/00, C12N 15/861
US Classification:
514 44 R, 4353021
Abstract:
The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.
Membrane Resident Peptide In Anti-Cancer Peptides Causes Tumor Cell Necrosis Rather Than Apoptosis Of Cancer Cells
Membrane Resident Peptide In Anti-Cancer Peptides Causes Tumor Cell Necrosis Rather Than Apoptosis Of Cancer Cells
US Patent:
2012017, Jul 12, 2012
Filed:
Oct 2, 2009
Appl. No.:
13/122256
Inventors:
Matthew R. Pincus - Brooklyn NY, US
Josef Michl - Little Neck NY, US
Josef Michl - Little Neck NY, US
International Classification:
A61K 39/395, A61K 51/00, A61K 38/02, G01N 33/566, C12Q 1/04, C12Q 1/25, G01N 21/64, A61P 35/00, C12N 5/09, C12Q 1/02
US Classification:
424 111, 435375, 4241741, 514 193, 435 29, 435 34, 435 723
Abstract:
An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
Peptides Selectively Lethal To Malignant And Transformed Mammalian Cells
Peptides Selectively Lethal To Malignant And Transformed Mammalian Cells
US Patent:
2004003, Feb 26, 2004
Filed:
Mar 12, 2003
Appl. No.:
10/386737
Inventors:
Matthew Pincus - Brooklyn NY, US
International Classification:
A61K038/10, A61K038/08, C07K007/08, A61K039/21
US Classification:
514/014000, 514/015000, 514/016000, 530/326000, 530/327000, 530/328000, 424/188100
Abstract:
The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membrane-penetrating leader sequence are also provided.
Colorimetric Method For Determination Of 5-Hydroxyindoleacetic Acid
Colorimetric Method For Determination Of 5-Hydroxyindoleacetic Acid
US Patent:
5270215, Dec 14, 1993
Filed:
Dec 24, 1992
Appl. No.:
7/996555
Inventors:
Matthew R. Pincus - Brooklyn NY
Harry Mukerjee - Haverstraw NY
Harry Mukerjee - Haverstraw NY
International Classification:
G01N 3300, G01N 2177, G01J 342
US Classification:
436 96
Abstract:
A spectrophotometric assay for quantitative determination of 5-hydroxyindoleacetic acid in fluid samples. 3-methyl-2-benzthiazolone hydrazone is oxidized with sodium periodate to the corresponding diazonium salt. The resulting diazonium salt adds electrophilically to activated positions on indole ring of 5-hydroxyindoleacetic acid to yield azo dyes which absorb light at 510 nm.
Small Molecule Cancer Treatments That Cause Necrosis In Cancer Cells But Do Not Affect Normal Cells
Small Molecule Cancer Treatments That Cause Necrosis In Cancer Cells But Do Not Affect Normal Cells
US Patent:
2011018, Jul 28, 2011
Filed:
Nov 26, 2008
Appl. No.:
12/744831
Inventors:
Matthew R. Pincus - Brooklyn NY, US
Josef Michl - Little Neck NY, US
Josef Michl - Little Neck NY, US
International Classification:
A61K 38/16, C12Q 1/02, C12N 5/09, C07D 403/04, A61K 38/10, A61K 31/496, A61P 35/00
US Classification:
514 193, 435 29, 435375, 544370, 51425405
Abstract:
A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.